• Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)

  • Mar 2 2021
  • Durée: 22 min
  • Podcast

Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)

  • Résumé

  • Professor Marc Fisher and Dr Clay Johnston discuss the THALES trial, explaining its rationale, key results and subgroup analyses, and also comment on the potential clinical implications of CHANCE 2.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/

    Voir plus Voir moins

Ce que les auditeurs disent de Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.